File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects of treatment with Sandostatin® LAP® on small dense LDL and remnant-like lipoproteins in patients with acromegaly

TitleEffects of treatment with Sandostatin® LAP® on small dense LDL and remnant-like lipoproteins in patients with acromegaly
Authors
Issue Date2003
PublisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664
Citation
Clinical Endocrinology, 2003, v. 59 n. 5, p. 558-564 How to Cite?
AbstractOBJECTIVE: Acromegalic patients have been shown to have an increase in the concentrations of small dense low-density lipoprotein (LDL) and remnant-like lipoprotein particles (RLP).These lipoproteins are atherogenic and may contribute to the cardiovascular risk of these patients. The aim of this study was to determine whether treatment of acromegaly using Sandostatin® LAR® could lower these atherogenic lipoproteins. METHODS: Fourteen patients with active acromegaly were recruited and Sandostatin® LAP®, a long-acting somatostatin analogue, was given every 4 weeks by intramuscular injection for 6 months. Fasting lipids, lipoproteins, lipolytic enzymes were determined at baseline, 12 and 24 weeks after treatment. Small dense LDL was measured using density gradient ultracentrifugation and RLP-cholesterol (RLP-C) by an immunoseparation assay. RESULTS: There was already a marked reduction in GH and IGF-1 by week 8 and, in all subjects, IGF-1 levels within their respective age-specific normal range were achieved. At week 12, plasma triglyceride significantly decreased (P < 0.01) and both HDL2 (P < 0.01) and HDL3 (P < 0.01) subfractions increased. A reduction was seen in small dense LDL concentration (P < 0.05) and RLP-C (P < 0.05). Lipoprotein lipase (LPL) activity increased (P < 0.01 ) and the magnitude of the increase in LPL activity correlated with the increase in HDL at 3 months (r = 0.55, P < 0.05) but not with the changes in plasma triglyceride, small dense LDL or RLP-C. The improvement in plasma lipids and lipoproteins persisted until the end of the study. CONCLUSION: Sandostatin® LAR® is effective in the treatment of acromegaly and is associated with favourable changes in plasma lipids and a reduction in small dense LDL and RLP-C.
Persistent Identifierhttp://hdl.handle.net/10722/162731
ISSN
2015 Impact Factor: 3.487
2015 SCImago Journal Rankings: 1.314
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTan, KCBen_HK
dc.contributor.authorPang, RWCen_HK
dc.contributor.authorTiu, SCen_HK
dc.contributor.authorLam, KSLen_HK
dc.date.accessioned2012-09-05T05:22:51Z-
dc.date.available2012-09-05T05:22:51Z-
dc.date.issued2003en_HK
dc.identifier.citationClinical Endocrinology, 2003, v. 59 n. 5, p. 558-564en_HK
dc.identifier.issn0300-0664en_HK
dc.identifier.urihttp://hdl.handle.net/10722/162731-
dc.description.abstractOBJECTIVE: Acromegalic patients have been shown to have an increase in the concentrations of small dense low-density lipoprotein (LDL) and remnant-like lipoprotein particles (RLP).These lipoproteins are atherogenic and may contribute to the cardiovascular risk of these patients. The aim of this study was to determine whether treatment of acromegaly using Sandostatin® LAR® could lower these atherogenic lipoproteins. METHODS: Fourteen patients with active acromegaly were recruited and Sandostatin® LAP®, a long-acting somatostatin analogue, was given every 4 weeks by intramuscular injection for 6 months. Fasting lipids, lipoproteins, lipolytic enzymes were determined at baseline, 12 and 24 weeks after treatment. Small dense LDL was measured using density gradient ultracentrifugation and RLP-cholesterol (RLP-C) by an immunoseparation assay. RESULTS: There was already a marked reduction in GH and IGF-1 by week 8 and, in all subjects, IGF-1 levels within their respective age-specific normal range were achieved. At week 12, plasma triglyceride significantly decreased (P < 0.01) and both HDL2 (P < 0.01) and HDL3 (P < 0.01) subfractions increased. A reduction was seen in small dense LDL concentration (P < 0.05) and RLP-C (P < 0.05). Lipoprotein lipase (LPL) activity increased (P < 0.01 ) and the magnitude of the increase in LPL activity correlated with the increase in HDL at 3 months (r = 0.55, P < 0.05) but not with the changes in plasma triglyceride, small dense LDL or RLP-C. The improvement in plasma lipids and lipoproteins persisted until the end of the study. CONCLUSION: Sandostatin® LAR® is effective in the treatment of acromegaly and is associated with favourable changes in plasma lipids and a reduction in small dense LDL and RLP-C.en_HK
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664en_HK
dc.relation.ispartofClinical Endocrinologyen_HK
dc.rightsClinical Endocrinology. Copyright © Blackwell Publishing Ltd.-
dc.subject.meshAcromegaly - Drug Therapyen_US
dc.subject.meshAdulten_US
dc.subject.meshAntineoplastic Agents, Hormonal - Therapeutic Useen_US
dc.subject.meshApolipoprotein A-I - Analysisen_US
dc.subject.meshBlood Glucose - Analysisen_US
dc.subject.meshCholesterol - Blooden_US
dc.subject.meshDelayed-Action Preparationsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHemoglobin A, Glycosylated - Analysisen_US
dc.subject.meshHuman Growth Hormone - Blooden_US
dc.subject.meshHumansen_US
dc.subject.meshInsulin - Blooden_US
dc.subject.meshInsulin-Like Growth Factor I - Analysisen_US
dc.subject.meshLipoproteins - Blooden_US
dc.subject.meshLipoproteins, Hdl - Blooden_US
dc.subject.meshLipoproteins, Ldl - Blooden_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshOctreotide - Therapeutic Useen_US
dc.subject.meshTriglycerides - Blooden_US
dc.titleEffects of treatment with Sandostatin® LAP® on small dense LDL and remnant-like lipoproteins in patients with acromegalyen_HK
dc.typeArticleen_HK
dc.identifier.emailTan, KCB: kcbtan@hku.hken_HK
dc.identifier.emailPang, RWC: robertap@hkucc.hku.hken_HK
dc.identifier.emailLam, KSL: ksllam@hku.hken_HK
dc.identifier.authorityTan, KCB=rp00402en_HK
dc.identifier.authorityPang, RWC=rp00274en_HK
dc.identifier.authorityLam, KSL=rp00343en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1046/j.1365-2265.2003.01849.xen_HK
dc.identifier.pmid14616878-
dc.identifier.scopuseid_2-s2.0-0242351682en_HK
dc.identifier.hkuros85685-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0242351682&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume59en_HK
dc.identifier.issue5en_HK
dc.identifier.spage558en_HK
dc.identifier.epage564en_HK
dc.identifier.isiWOS:000186176400003-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridTan, KCB=8082703100en_HK
dc.identifier.scopusauthoridPang, RWC=7004376659en_HK
dc.identifier.scopusauthoridTiu, SC=7003310747en_HK
dc.identifier.scopusauthoridLam, KSL=8082870600en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats